BDC
MCID: CLL002
MIFTS: 64

Collecting Duct Carcinoma (BDC)

Categories: Bone diseases, Cancer diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Collecting Duct Carcinoma

MalaCards integrated aliases for Collecting Duct Carcinoma:

Name: Collecting Duct Carcinoma 11 19 58 14 16 75
Kidney Medullary Carcinoma 19 28 16 71
Renal Medullary Carcinoma 11 19 58
Collecting Duct Carcinoma of the Kidney 19 71
Renal Cell Adenocarcinoma 19 16
Bellini Duct Carcinoma 19 58
Bellini Carcinoma 19 58
Bdc 19 58
Cdc 19 58
Renal Carcinoma, Collecting Duct Type 11
Carcinoma of Renal Collecting Duct 11
Renal Collecting Duct Carcinoma 19
Adenocarcinoma of Kidney 19
Bellini's Duct Carcinoma 19
Renal Cell Carcinoma 19

Characteristics:


Prevelance:

Collecting Duct Carcinoma: <1/1000000 (Europe) 58
Renal Medullary Carcinoma: <1/1000000 (Europe) 58

Age Of Onset:

Collecting Duct Carcinoma: Adult 58
Renal Medullary Carcinoma: Adult 58

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 11 DOID:4464
MeSH 43 D002292
NCIt 49 C6194
SNOMED-CT 68 733470002
MESH via Orphanet 44 D002292
ICD10 via Orphanet 32 C64
UMLS via Orphanet 72 C1266044
UMLS 71 C1266044 C4049328

Summaries for Collecting Duct Carcinoma

Orphanet 58 Collecting duct carcinoma: Collecting duct carcinoma is a rare, aggressive subtype of renal cell carcinoma, which originates from the epithelium of the distal collecting ducts, and usually manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Patients are often asymptomatic for long periods of time and therefore, disease is often locally advanced or metastatic at the time of diagnosis. In cases with metastatic spread, bone pain, cough, dyspnea, pneumonia or neurological compromise may be associated.

Renal medullary carcinoma: Renal medullary carcinoma is a rare, aggressive subtype of renal cell carcinoma characterized by a large, white or tan, firm, infiltrative tumor with microabscess-like foci centered in the renal medulla, typically presenting with hematuria, abdominal/flank pain, weight loss and fever. It is associated with sickle cell trait and disease and metastasis to the bones and lungs is common at time of diagnosis.

MalaCards based summary: Collecting Duct Carcinoma, also known as kidney medullary carcinoma, is related to von hippel-lindau syndrome and hereditary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Collecting Duct Carcinoma is XIST (X Inactive Specific Transcript), and among its related pathways/superpathways are Clear cell renal cell carcinoma pathways and Type 2 papillary renal cell carcinoma. The drugs Gemcitabine and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and t cells, and related phenotypes are liver/biliary system and embryo

GARD: 19 Collecting duct carcinoma (CDC) is a rare and aggressive form of kidney cancer that begins in the collecting duct of the kidney. Many people with CDC have no symptoms until the cancer is at an advanced stage. Symptoms may include flank pain, unexplained weight loss, or blood in the urine. Although it can affect people of all ages, CDC tends to occur in younger patients. The exact cause of CDC is unknown. It usually occurs in people with no family history of the condition.

Disease Ontology: 11 A renal cell carcinoma that begins in distal collecting ducts of the kidney with a tubulopapillary morphology and intracytoplasmic mucicarminophilic material.

Wikipedia: 75 Collecting duct carcinoma (CDC) is a type of kidney cancer that originates in the papillary duct of the... more...

Related Diseases for Collecting Duct Carcinoma

Diseases related to Collecting Duct Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1821)
# Related Disease Score Top Affiliating Genes
1 von hippel-lindau syndrome 32.8 VHL FLCN FH
2 hereditary renal cell carcinoma 32.4 VHL TFE3 RNF139 PBRM1 FLCN FH
3 multilocular clear cell renal cell carcinoma 32.4 FLCN CDH16
4 mucinous tubular and spindle renal cell carcinoma 32.2 TFE3 MME KRT7 AMACR
5 childhood kidney cell carcinoma 31.8 TFEB TFE3 PRCC ASPSCR1
6 eosinophilic variant of chromophobe renal cell carcinoma 31.8 TFEB TFE3 KRT7 CDH16
7 bap1 tumor predisposition syndrome 31.7 VHL SMARCB1 FLCN FH ALK
8 renal cell carcinoma, xp11-associated 31.6 TFEB TFE3 PRCC ASPSCR1
9 papillary carcinoma 31.4 PBRM1 PAX8 KRT7
10 kidney cancer 31.3 VHL SETD2 FLCN FH
11 birt-hogg-dube syndrome 31.2 TFEB TFE3 KRT7 FLCN FH CDH16
12 kidney angiomyolipoma 31.1 TFE3 FLCN
13 fumarate hydratase deficiency 31.0 VHL FH
14 xanthogranulomatous pyelonephritis 30.9 TFE3 MME KRT7
15 pheochromocytoma 30.8 VHL SETD2 MME KRT7 FH
16 metanephric adenoma 30.8 TFE3 PRCC PAX8 PAX2 MME KRT7
17 hemangioblastoma 30.7 VHL PAX8 PAX2 MME
18 cystadenoma 30.7 VHL MME KRT7
19 hydronephrosis 30.6 PAX2 MME KRT7
20 leiomyomatosis 30.6 VHL FLCN FH
21 renal pelvis carcinoma 30.6 SETD2 PBRM1 KRT7
22 inherited cancer-predisposing syndrome 30.6 VHL SMARCB1 FLCN FH ALK
23 familial renal papillary carcinoma 30.6 TFE3 FLCN FH
24 vascular cancer 30.6 TFE3 KRT7 ASPSCR1
25 papillary adenoma 30.5 TFE3 PAX8 KRT7 AMACR
26 nephroma 30.5 TFE3 MME ALK
27 peritoneal mesothelioma 30.4 SETD2 PAX8 KRT7
28 cholangiocarcinoma 30.4 PBRM1 OGG1 MME KRT7
29 renal pelvis adenocarcinoma 30.4 PAX8 KRT7
30 chordoma 30.4 SMARCB1 SETD2 PBRM1 KRT7
31 sarcomatoid renal cell carcinoma 30.4 PBRM1 PAX8 MME KRT7
32 clear cell meningioma 30.4 SMARCB1 PBRM1
33 chronic pyelonephritis 30.4 MME KRT7
34 myoepithelial carcinoma 30.3 SMARCB1 KRT7
35 cystic kidney disease 30.2 VHL PAX2 FLCN FH
36 mixed germ cell cancer 30.1 PAX8 KRT7
37 paraganglioma 30.1 VHL SETD2 KRT7 FH
38 krukenberg carcinoma 30.1 PAX8 KRT7
39 lymphangitis 30.1 KRT7 ALK
40 microcystic adenoma 30.1 VHL MME
41 hidradenoma 30.1 MME KRT7
42 renal oncocytoma 30.0 TFEB TFE3 PAX8 MME KRT7 FLCN
43 leiomyoma cutis 30.0 TFE3 FLCN FH
44 mesenchymal cell neoplasm 30.0 TFE3 SMARCB1 MME ALK
45 carcinosarcoma 30.0 PAX8 MME KRT7
46 cutaneous leiomyosarcoma 30.0 MME FLCN FH
47 mucinous adenocarcinoma 29.9 PAX8 KRT7 ALK
48 vaginal cancer 29.9 MME KRT7
49 intrahepatic bile duct adenoma 29.9 MME KRT7
50 alveolar soft part sarcoma 29.9 TFEB TFE3 SMARCB1 PRCC PAX8 ASPSCR1

Graphical network of the top 20 diseases related to Collecting Duct Carcinoma:



Diseases related to Collecting Duct Carcinoma

Symptoms & Phenotypes for Collecting Duct Carcinoma

UMLS symptoms related to Collecting Duct Carcinoma:


flank pain

MGI Mouse Phenotypes related to Collecting Duct Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.76 AMACR ASPSCR1 MME OGG1 PBRM1 RNF139
2 embryo MP:0005380 9.61 FLCN PAX2 PAX8 PBRM1 SETD2 SMARCB1
3 mortality/aging MP:0010768 9.47 ALK AMACR FH FLCN OGG1 PAX2

Drugs & Therapeutics for Collecting Duct Carcinoma

Drugs for Collecting Duct Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 378)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4 95058-81-4, 122111-03-9 60750
2
Sunitinib Approved, Investigational Phase 4 557795-19-4 5329102
3
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
4 Antimetabolites Phase 4
5
Sargramostim Approved, Investigational Phase 3 123774-72-1
6
Racepinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4, 329-65-7 838 5816
7
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 437-38-7 3345
9
Clonidine Approved Phase 2, Phase 3 4205-91-8, 4205-90-7 2803 20179
10
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
11
Promethazine Approved, Investigational Phase 3 60-87-7 4927
12
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4
13
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 6279 10631
14
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
15
Memantine Approved, Investigational Phase 3 41100-52-1, 19982-08-2 4054
16
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
17
Zoledronic acid Approved Phase 3 118072-93-8 68740
18
Denosumab Approved Phase 3 615258-40-7
19
Isotretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4, 4759-48-2 5538 444795 5282379
20
Molgramostim Investigational Phase 3 99283-10-0
21
Abexinostat Investigational Phase 3 783355-60-2 11749858
22
Vorolanib Investigational Phase 3 1013920-15-4
23 Analgesics Phase 3
24 Analgesics, Non-Narcotic Phase 3
25 Interferon alpha-2 Phase 3
26 interferons Phase 3
27 Interferon-alpha Phase 3
28 Epinephryl borate Phase 2, Phase 3
29 Adrenergic Agents Phase 2, Phase 3
30 Adrenergic alpha-Agonists Phase 2, Phase 3
31 Adrenergic Agonists Phase 2, Phase 3
32 Sympatholytics Phase 2, Phase 3
33 Histamine H1 Antagonists Phase 3
34 Histamine Antagonists Phase 3
35 Antineoplastic Agents, Hormonal Phase 3
36 Shark Cartilage Phase 3
37 Contraceptives, Oral, Hormonal Phase 3
38 Contraceptives, Oral Phase 3
39 Contraceptive Agents, Male Phase 3
40 Contraceptive Agents Phase 3
41 Neurotransmitter Agents Phase 3
42 Dopamine Agents Phase 3
43 Antiparkinson Agents Phase 3
44 Excitatory Amino Acid Antagonists Phase 3
45
Trametinib Approved Phase 2 871700-17-3 11707110
46
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
47
Osimertinib Approved Phase 2 1421373-65-0 71496458
48
Vinblastine Approved Phase 2 865-21-4 241903 13342
49
Aflibercept Approved Phase 2 862111-32-8 124490314
50
Etoposide Approved Phase 2 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 1244)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
3 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies Completed NCT00414765 Phase 4 Aldesleukin
5 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Completed NCT02596035 Phase 4 Nivolumab
6 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
7 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
8 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
9 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
10 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
11 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
12 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Completed NCT02982954 Phase 4 Nivolumab;Ipilimumab
13 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Recruiting NCT04513522 Phase 4
14 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02570789 Phase 4 patients with sunitinib or pazopanib
15 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
16 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
17 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
18 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
19 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
20 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
21 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma Completed NCT02627963 Phase 3 tivozanib hydrochloride;Sorafenib
22 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Completed NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
23 A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma Completed NCT00732914 Phase 3 Sunitinib (Sutent);Sorafenib (Nexavar)
24 Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed NCT00720941 Phase 3 Pazopanib;Sunitinib
25 Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO] Completed NCT00416871 Phase 3
26 An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 Completed NCT00387764 Phase 3 pazopanib
27 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
28 A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
29 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Interferon-Alfa 9MU
30 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
31 An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma Completed NCT00478114 Phase 3 sorafenib
32 A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy Completed NCT00474786 Phase 3 Sorafenib;temsirolimus (Torisel)
33 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
34 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
35 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
36 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
37 An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301). Completed NCT01076010 Phase 3 Tivozanib;Sorafenib
38 A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma. Completed NCT00065468 Phase 3 Interferon Alfa;CCI-779;Interferon Alfa and CCI-779
39 Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma Completed NCT00053807 Phase 3 fluorouracil
40 Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
41 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib
42 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma. Completed NCT01064310 Phase 3 pazopanib;sunitinib
43 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1) Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
44 A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
45 Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma Completed NCT00005966 Phase 3 thalidomide
46 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3
47 A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00053820 Phase 3 fluorouracil
48 AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy Completed NCT00005995 Phase 3 shark cartilage extract AE-941
49 A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed NCT02420821 Phase 3 Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;Bevacizumab;Sunitinib
50 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)

Search NIH Clinical Center for Collecting Duct Carcinoma

Genetic Tests for Collecting Duct Carcinoma

Genetic tests related to Collecting Duct Carcinoma:

# Genetic test Affiliating Genes
1 Kidney Medullary Carcinoma 28

Anatomical Context for Collecting Duct Carcinoma

Organs/tissues related to Collecting Duct Carcinoma:

MalaCards : Kidney, Bone, T Cells, Lymph Node, Endothelial, Lung, Adrenal Gland

Publications for Collecting Duct Carcinoma

Articles related to Collecting Duct Carcinoma:

(show top 50) (show all 30589)
# Title Authors PMID Year
1
Current and Future Biomarkers in the Management of Renal Cell Carcinoma. 62
36424079 2023
2
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. 62
36328922 2023
3
[Retracted] miR‑148a suppresses human renal cell carcinoma malignancy by targeting AKT2. 62
36453255 2023
4
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma. 62
36280529 2023
5
Isolated Urinary Bladder Metastasis in Renal Cell Carcinoma Detected on 18F-FDG PET/CT Scan. 62
36469073 2023
6
Synchronous hepatocellular carcinoma and renal cell carcinoma in young woman with sarcoidosis: A case report. 62
36411849 2023
7
Special issue "The advance of solid tumor research in China": Presurgical therapy in the management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. 62
35712762 2023
8
Ultrasound findings of subcutaneous soft tissue metastasis of renal cell carcinoma: A case report. 62
36340234 2023
9
Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. 62
36327112 2023
10
NEK2 is associated with poor prognosis of clear cell renal cell carcinoma and promotes tumor cell growth and metastasis. 62
36370999 2023
11
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. 62
36441070 2023
12
Can microRNAs be utilized as tumor markers for recurrence following nephrectomy in renal cell carcinoma patients? A meta-analysis provides the answer. 62
36280530 2023
13
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. 62
36472582 2023
14
Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. 62
35751420 2023
15
Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response. 62
35579992 2023
16
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. 62
35130111 2022
17
A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. 62
34092479 2022
18
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. 62
36327527 2022
19
Unexpected Detection of Skeletal Muscle Renal Cell Carcinoma Metastasis With 99m Tc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd) Scan. 62
35619201 2022
20
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. 62
35819272 2022
21
The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. 62
35843777 2022
22
Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. 62
35037540 2022
23
Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma Metastases. 62
36413679 2022
24
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy. 62
36381657 2022
25
GBP2 serves as a novel prognostic biomarker and potential immune microenvironment indicator in renal cell carcinoma. 62
36222186 2022
26
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. 62
36190538 2022
27
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. 62
35869002 2022
28
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. 62
35616728 2022
29
Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma. 62
36474188 2022
30
Dry and wet experiments reveal the significant role of FUT11 in clear cell renal cell carcinoma. 62
36403525 2022
31
Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors. 62
36403521 2022
32
Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment? 62
35945083 2022
33
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study. 62
36050262 2022
34
Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. 62
36093731 2022
35
Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. 62
36028785 2022
36
Clinical study of centrality index in predicting the postoperative pathological nuclear grade of clear cell renal cell carcinoma. 62
36030357 2022
37
CircSCNN1A is a tumor suppressor in renal cell carcinoma via inducing the upregulation of MPP7 by the sponge effect on miR-421. 62
36343886 2022
38
Transarterial embolization of T1b and T2a renal cell carcinoma prior to percutaneous cryoablation: a retrospective comparative study. 62
36454278 2022
39
Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial. 62
36464531 2022
40
Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence? 62
36325369 2022
41
Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging. 62
36342807 2022
42
Quality-of-life reporting in randomized controlled trials shaping the EAU Renal Cell Carcinoma Guidelines. 62
36396089 2022
43
SKA1 promotes tumor metastasis via SAFB-mediated transcription repression of DUSP6 in clear cell renal cell carcinoma. 62
36462498 2022
44
Blood Perfusion Characteristics of Renal Cell Carcinoma in the Process of Tumor Growth: Monitored With Multiple Sonographic Modalities. 62
36165634 2022
45
Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma. 62
36220718 2022
46
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing. 62
36205930 2022
47
Epigenetics in advanced renal cell carcinoma: Potential new targets. 62
36257538 2022
48
Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation. 62
35713705 2022
49
Sunitinib maleate administration before percutaneous CT-guided cryoablation for large renal cell carcinoma: A case report. 62
36238214 2022
50
Proteogenomic characterization of MiT family translocation renal cell carcinoma. 62
36470859 2022

Variations for Collecting Duct Carcinoma

Cosmic variations for Collecting Duct Carcinoma:

8 (show top 50) (show all 896)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88297043 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 28
2 COSM90657935 VHL kidney,NS,carcinoma,renal cell c.362G>T p.C121F 3:10149808-10149808 28
3 COSM85360217 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176= 3:124737785-124737785 28
4 COSM93517001 TRIO kidney,NS,carcinoma,renal cell c.1505A>G p.N502S 5:14508136-14508136 28
5 COSM143919608 TRIO kidney,NS,carcinoma,renal cell c.706-1273A>G p.? 5:14508136-14508136 28
6 COSM89062698 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 28
7 COSM143371158 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.700C>T p.R234C 17:7673803-7673803 28
8 COSM142560569 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.700C>T p.R234C 17:7673803-7673803 28
9 COSM144013689 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.784C>T p.R262C 17:7673803-7673803 28
10 COSM112253896 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
11 COSM121876485 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.421C>T p.R141C 17:7673803-7673803 28
12 COSM87898723 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
13 COSM142837563 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
14 COSM144651456 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.700C>T p.R234C 17:7673803-7673803 28
15 COSM143944164 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.340C>T p.R114C 17:7673803-7673803 28
16 COSM143157028 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.340C>T p.R114C 17:7673803-7673803 28
17 COSM122271832 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.421C>T p.R141C 17:7673803-7673803 28
18 COSM106053452 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
19 COSM122734408 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.421C>T p.R141C 17:7673803-7673803 28
20 COSM144087282 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.340C>T p.R114C 17:7673803-7673803 28
21 COSM144310445 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.700C>T p.R234C 17:7673803-7673803 28
22 COSM93184014 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
23 COSM145017959 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.700C>T p.R234C 17:7673803-7673803 28
24 COSM105620655 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.782+378C>T p.? 17:7673803-7673803 28
25 COSM111758883 TP53 kidney,NS,carcinoma,collecting duct carcinoma c.817C>T p.R273C 17:7673803-7673803 28
26 COSM90865192 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 28
27 COSM94389604 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 28
28 COSM94442225 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 28
29 COSM94492333 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 28
30 COSM92824042 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 28
31 COSM94232725 RABGAP1 kidney,NS,carcinoma,renal cell c.1749T>A p.H583Q 9:123020414-123020414 28
32 COSM106795558 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
33 COSM130825760 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
34 COSM94057597 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
35 COSM126664114 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
36 COSM131800227 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
37 COSM114430588 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 28
38 COSM100863866 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 28
39 COSM129143197 KMT2A kidney,NS,carcinoma,renal cell c.5720C>T p.A1907V 11:118497991-118497991 28
40 COSM144159091 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 28
41 COSM96915510 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 28
42 COSM86472399 H2BC1 kidney,NS,carcinoma,renal cell c.239C>A p.S80* 6:25727147-25727147 28
43 COSM146087884 DOCK1 kidney,NS,carcinoma,renal cell c.1369G>T p.D457Y 10:127023241-127023241 28
44 COSM88845534 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 28
45 COSM102230151 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 28
46 COSM137305195 DDX19B kidney,NS,carcinoma,renal cell c.558G>A p.V186= 16:70325624-70325624 28
47 COSM137613380 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 28
48 COSM136951592 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 28
49 COSM88298617 DDX19B kidney,NS,carcinoma,renal cell c.543G>A p.V181= 16:70325624-70325624 28
50 COSM92903161 DDX19B kidney,NS,carcinoma,renal cell c.450G>A p.V150= 16:70325624-70325624 28

Expression for Collecting Duct Carcinoma

Search GEO for disease gene expression data for Collecting Duct Carcinoma.

Pathways for Collecting Duct Carcinoma

Pathways related to Collecting Duct Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.06 VHL SETD2 PBRM1
2 10.63 VHL TFEB TFE3 SETD2 PRCC FH

GO Terms for Collecting Duct Carcinoma

Biological processes related to Collecting Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell differentiation GO:0045597 10.01 VHL SMARCB1 PBRM1
2 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.83 PAX8 PAX2
3 pronephros development GO:0048793 9.81 PAX8 PAX2
4 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.8 PAX8 PAX2
5 metanephric epithelium development GO:0072207 9.78 PAX8 PAX2
6 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.76 PAX2 PAX8
7 metanephric distal convoluted tubule development GO:0072221 9.73 PAX2 PAX8
8 metanephric nephron tubule formation GO:0072289 9.71 PAX2 PAX8
9 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.67 PAX8 PAX2
10 positive regulation of metanephric DCT cell differentiation GO:2000594 9.62 PAX8 PAX2
11 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.56 PAX8 PAX2
12 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.46 PAX8 PAX2
13 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.26 PAX8 PAX2
14 pronephric field specification GO:0039003 8.92 PAX8 PAX2

Sources for Collecting Duct Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....